Fidia main sponsor of the inauguration of the first Esaso Italian campus

On the occasion of the inaugural ceremony of the first Italian training center of ESASO (European School for Advanced Studies in Ophthalmology), Fidia Farmaceutici renews its support both in the field of higher education and in preclinical and clinical research.

On Friday 10 December during the inauguration ceremony of a new training center in Parma, Fidia was again next to ESASO (European School for Advanced Studies in Ophthalmology), the prestigious School that the company has supported since 2017.

This is the first ESASO campus in Italy, the fourth in the world, in addition to equivalent institutes in Lublin, Singapore and Lugano. Housed in the Department of Medicine and Surgery of the University of Parma, the new center specializes in the treatment of glaucoma.

The aim of the School is to provide its students with a more practical approach to ophthalmology by facilitating the dissemination of new and effective ophthalmological learning and expertise: in order to do this ESASO has built strong partnerships with leading ophthalmic institutions, groups and companies around the world, including Fidia Farmaceutici, leader in the ophthalmic sector in Italy.

The speech by the Vice Rector of the University of Parma, Paolo Martelli, was followed by the interventions of Borja Corcóstegui, President of the ESASO Foundation Board, Francesco Bandello, member of the ESASO Foundation Board, Stefano Gandolfi, Scientific Director of the ESASO campus of Parma, Robert Rejdak, Scientific Director of the ESASO Campus in Lublin, Giuseppe Guarnaccia, Executive Director of ESASO and Dr. Carlo Pizzocaro, President and CEO of Fidia Farmaceutici.

"At Fidia, we consider the importance of research and theoretical-practical continuous training to be fundamental - underlined Carlo Pizzocaro in his speech - We are therefore proud to support ESASO's commitment in higher education, which in Parma will also have the aim of developing new treatments and therapeutic solutions for glaucoma".


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine